Recombinant Human Serpin A7/TBG Protein, CF Summary
Ala21-Ala415, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.|
|Reconstitution||Reconstitute at 1 mg/mL in water.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Thyroxine-BSA Conjugate is immobilized at 2.5 μg/mL, 100 μL/well, Recombinant Human Serpin A7/TBG (Catalog # 9564-PI) binds with an ED50 of 0.4-2 μg/mL.
Background: Serpin A7/TBG
Thyroxine-binding globulin (TBG), also known as Serpin A7, is an approximately 44 kDa member of the serpin superfamily of serine protease inhibitors. TBG belongs to the clade A subgroup of serpins which include inflammatory response molecules (1). Human TBG shares 76% sequence identity to mouse TBG. TBG is one of two serpins known to bind and transport hormones. TBG is responsible for binding the majority of thyroxine (T4) in the blood and releasing it through conformational changes in the reactive loop (2). In addition, cleavage of TBG's reactive site loop by proteases present at inflammatory sites causes a targeted and immediate release of thyroxine from TBG (3). TBG levels are modified by estrogen levels (4-6) and may directly predict perinatal syndromal depression in late pregnancy (6). In addition, elevated TBG levels were a reported marker for chronic obstructive pulmonary disease (7) in support of reported endocrine system dysfunction in patients with the disease (8, 9).
- Law, R. et al. (2006) Genome Biol. 7:216.
- Zhou, A. et al. (2006) Proc. Natl. Acad. Sci. USA 103:13321.
- Jirasakuldech, B. et al. (2000) J. Clin. Endocrinol. Metab. 85:3996.
- Glinoer, D. (1997) Endocr. Rev. 18:404.
- Gaberscek, S. and K. Zaletel (2011) Expert Rev. Clin. Immunol. 7:697.
- Pedersen, C. et al. (2016) Psychoneuroendocrinology 65:84.
- Diao, W. et al. (2017) Int. J. Chron. Obstruct. Pulmon. Dis. 12: 1549.
- Terzano, C et al. (2014) Lung 192:103.
- Sarinc Ulasli, S. et al. (2013) Multidiscip. Respir. Med. 8:64.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human Serpin A7/TBG Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Serpin A7/TBG Protein, CF and earn rewards!
Have you used Recombinant Human Serpin A7/TBG Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image